---
title: "Agentix (AGTX) stock listing, news and investor profile"
url: "https://aibio.space/companies/agentix/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Agentix Corp. (OTC: AGTX), United States. The directory classifies it as Pharmaceuticals: Major."
---

AGTX Agentix Corp. OTC · United States

# Agentix (AGTX) news

Distress · 2025-08-15

## [Agentix Corp. says its June quarter report will be late](https://aibio.space/news/agentix-corp-says-june-quarter-report-will-late/)

Agentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025.

## Latest Agentix news

We have not published a story on Agentix yet. When there is news, it will appear here.

## Agentix at a glance

- **Ticker**: AGTX

- **Listing**: OTC

- **Country**: United States

- **Cash, Jun 30, 2026**: $38

### Related companies

- [MERA PHARMACEUTICALS INC](https://aibio.space/companies/mera-pharmaceuticals/) OTC: MRPI
- [Connect Biopharma Holdings](https://aibio.space/companies/connect-biopharma/) NASDAQ: CNTB
- [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA
- [TETRALOGIC PHARMACEUTICALS CORP](https://aibio.space/companies/tetralogic-pharmaceuticals/) OTC: TLOG
- [Lexicon Pharmaceuticals](https://aibio.space/companies/lexicon-pharmaceuticals/) NASDAQ: LXRX
- [Kaleido Biosciences](https://aibio.space/companies/kaleido-biosciences/) OTC: KLDO
- [Silo Pharma](https://aibio.space/companies/silo-pharma/) NASDAQ: SILO
- [Palisade Bio](https://aibio.space/companies/palisade-bio/) NASDAQ: PALI

### Also on OTC

- [eFFECTOR Therapeutics](https://aibio.space/companies/effector-therapeutics/) EFTR
- [RegeneRx Biopharmaceuticals](https://aibio.space/companies/regenerx-biopharmaceuticals/) RGRX
- [CANNAPHARMARX, INC.](https://aibio.space/companies/cannapharmarx/) CPMD
- [Revium Rx.](https://aibio.space/companies/revium-rx/) RVRC
- [Asep Medical Holdings](https://aibio.space/companies/asep-medical/) SEPSF
- [Rafarma Pharmaceuticals, Inc. (WY)](https://aibio.space/companies/rafarma-pharmaceuticals-wy/) RAFA

## What Agentix does

Agentix Corp. is a clinical development stage company focused on developing and commercializing novel therapeutics for metabolic disease. Its principal business objective is to develop two assets designed to be peripherally restricted, meaning they do not cross the blood brain barrier. Both target the peripheral CB1 receptor, which is involved in regulating glucose and lipid metabolism, for conditions including obesity, type 2 diabetes and nonalcoholic fatty liver disease. The company has not yet generated or realized meaningful revenues. Its lead candidate, AGTX-2004, is a peripherally-acting CB1 receptor antagonist. Its IND application was cleared by the FDA, and the company is preparing a Phase 1 safety and tolerability study in humans, to be managed by its Australian subsidiary, Agentix Australia Pty Ltd. The company licensed AGTX-2004 worldwide from Taiwan's National Health Research Institutes in March 2021. Its second asset, AGTX-2003, is in additional enabling animal studies ahead of an IND filing. The company plans to partner with larger biopharma players for the pivotal stages of commercialization.

| Product or program | What it is | Stage |
|---|---|---|
| AGTX-2004 (DBPR211) | Peripherally-acting CB1 receptor antagonist for obesity and type 2 diabetes | IND cleared by the FDA; preparing Phase 1 |
| AGTX-2003 (RTI-1092769) | Peripherally-acting CB1 receptor inverse agonist for obesity and NAFLD | enabling animal studies ahead of IND filing |

Summarised from the company's [10-K filed Jul 1, 2026](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/agtx_10k.htm).

## Agentix annual financials

| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Research and development | [$125,079](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) | [$180,987](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) |
| Net income (loss) | [-$485,636](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) | [-$567,048](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) |
| Cash from operations | [-$108,529](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) | [-$125,078](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) |
| Cash and equivalents | [$771](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/) | [$4,477](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004781/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $38.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Agentix

What is the ticker symbol of Agentix?

Agentix Corp. trades under the ticker AGTX on OTC.

Where is Agentix listed?

Agentix Corp. is listed on OTC.

What is the SEC CIK of Agentix?

The SEC Central Index Key (CIK) for Agentix Corp. is 1603345. Its filings are on SEC EDGAR.

How many shares does Agentix have outstanding?

40,066,951 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-10.

Which country or territory is Agentix listed under?

Our directory records Agentix Corp. under United States.

What does Agentix do?

Our directory classifies Agentix Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Agentix?

The ISIN recorded for Agentix Corp. is US00848A1034.

Does aibio.space cover Agentix?

aibio.space lists Agentix Corp. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Agentix incorporated?

SEC records list its state or country of incorporation as NV.

What does Agentix develop?

Agentix Corp. is a clinical development stage company focused on developing and commercializing novel therapeutics for metabolic disease. Its principal business objective is to develop two assets designed to be peripherally restricted, meaning they do not cross the blood brain barrier.

What is AGTX-2004 (DBPR211) from Agentix?

AGTX-2004 (DBPR211): Peripherally-acting CB1 receptor antagonist for obesity and type 2 diabetes Stage: IND cleared by the FDA; preparing Phase 1.

What is AGTX-2003 (RTI-1092769) from Agentix?

AGTX-2003 (RTI-1092769): Peripherally-acting CB1 receptor inverse agonist for obesity and NAFLD Stage: enabling animal studies ahead of IND filing.

Is Agentix profitable?

Agentix Corp. reported a net loss of $485,636 for the fiscal year ended Mar 31, 2026, and used $108,529 of cash in operations, per its annual report to the SEC.

How much does Agentix spend on research and development?

$125,079 in the fiscal year ended Mar 31, 2026, per its annual report.

How much cash does Agentix have?

$38 in cash at Jun 30, 2026, per its 10-Q.

## Investor discussion: Agentix

Members talk about Agentix (AGTX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Agentix, newest first. Each line links the filing it comes from.

1. 2025-08-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1603345/000147793225005988/agtx_nt10q.htm)
2. 2025-07-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1603345/000147793225004870/agtx_nt10k.htm)
3. 2025-02-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1603345/000147793225001033/agtx_nt10q.htm)
4. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1603345/000147793224007174/agtx_nt10q.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:AGTX on TradingView](https://www.tradingview.com/symbols/OTC-AGTX/).

## SEC filings and registration

- **SEC name**: Agentix Corp.

- **CIK**: 1603345

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: AGTX (OTC)

- **State or country of incorporation**: NV

- **Fiscal year ends**: March 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 32932 PACIFIC COAST HIGHWAY, DANA POINT, CA, 92629

- **Phone**: 321-229-2014

- **Shares outstanding**: 40,066,951 as of 2026-08-07 (10-Q filed 2026-08-10)

- **Former names**: FairWind Energy Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004781/agtx_10q.htm) filed 2026-08-10
- [10-K](https://www.sec.gov/Archives/edgar/data/1603345/000147793226004133/agtx_10k.htm) filed 2026-07-01
- [10-Q](https://www.sec.gov/Archives/edgar/data/1603345/000147793226000845/agtx_10q.htm) filed 2026-02-17
- [10-Q](https://www.sec.gov/Archives/edgar/data/1603345/000147793225008502/agtx_10q.htm) filed 2025-11-20
- [10-Q](https://www.sec.gov/Archives/edgar/data/1603345/000147793225006197/agtx_10q.htm) filed 2025-08-22
- [10-K](https://www.sec.gov/Archives/edgar/data/1603345/000147793225005077/agtx_10k.htm) filed 2025-07-16
- [10-Q](https://www.sec.gov/Archives/edgar/data/1603345/000147793225001090/agtx_10q.htm) filed 2025-02-18
- [10-Q](https://www.sec.gov/Archives/edgar/data/1603345/000147793224007361/agtx_10q.htm) filed 2024-11-18

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001603345), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Agentix Corp. is a public biotech or pharmaceutical company listed on OTC under the ticker AGTX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Agentix Corp.

- **Ticker**: AGTX

- **Listing**: OTC

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US00848A1034

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-AGTX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/agentix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Agentix (AGTX) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/agentix/